- Home
- TLSI vs SANG Comparison
TLSI vs SANG Comparison
Compare TLSI & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- SANG
- Stock Information
- Founded
- TLSI 2010
- SANG 1984
- Country
- TLSI United States
- SANG Canada
- Employees
- TLSI N/A
- SANG N/A
- Industry
- TLSI Medical Specialities
- SANG Computer Software: Programming Data Processing
- Sector
- TLSI Health Care
- SANG Technology
- Exchange
- TLSI Nasdaq
- SANG Nasdaq
- Market Cap
- TLSI 160.4M
- SANG 189.6M
- IPO Year
- TLSI N/A
- SANG 2021
- Fundamental
- Price
- TLSI $5.21
- SANG $5.45
- Analyst Decision
- TLSI Strong Buy
- SANG
- Analyst Count
- TLSI 5
- SANG 0
- Target Price
- TLSI $10.90
- SANG N/A
- AVG Volume (30 Days)
- TLSI 41.1K
- SANG 7.5K
- Earning Date
- TLSI 05-15-2025
- SANG 05-08-2025
- Dividend Yield
- TLSI N/A
- SANG N/A
- EPS Growth
- TLSI N/A
- SANG N/A
- EPS
- TLSI N/A
- SANG N/A
- Revenue
- TLSI $32,141,000.00
- SANG $238,264,000.00
- Revenue This Year
- TLSI $55.13
- SANG N/A
- Revenue Next Year
- TLSI $50.71
- SANG $2.91
- P/E Ratio
- TLSI N/A
- SANG N/A
- Revenue Growth
- TLSI 46.20
- SANG N/A
- 52 Week Low
- TLSI $3.50
- SANG $4.08
- 52 Week High
- TLSI $7.55
- SANG $7.99
- Technical
- Relative Strength Index (RSI)
- TLSI 46.54
- SANG 47.59
- Support Level
- TLSI $4.95
- SANG $5.37
- Resistance Level
- TLSI $5.68
- SANG $6.00
- Average True Range (ATR)
- TLSI 0.40
- SANG 0.25
- MACD
- TLSI 0.01
- SANG -0.06
- Stochastic Oscillator
- TLSI 39.74
- SANG 10.81
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.